Market Place
Sourcing Support
All News #Library
Rare Diseases
Johnson & Johnson Seeks FDA Approval For IMAAVY In wAIHA Anemia
25 Feb 2026 //
PR NEWSWIRE
EMA Seeks Input On Drafting Myasthenia Gravis Trial Guide
19 Feb 2026 //
RAPS
J&J gene therapy fails ph. 3 rare eye disease trial
06 May 2025 //
FIERCE BIOTECH
J&J positions nipocalimab to rival Vyvgart after hitting mark in myasthenia gravis trial
29 Jun 2024 //
PRESS RELEASE
Vanda gets $466M takeout bid from Cycle Pharma
06 Jun 2024 //
FIERCE PHARMA
J&J targets rare maternal-fetal disease: `We`re going for this.`
02 Apr 2024 //
FIERCE BIOTECH
TG Therapeutics’ shares jump as umbralisib wins FDA’s breakthrough status
22 Jan 2019 //
ENDPTS
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
AbbVie, J&J score early nod for Imbruvica in rare cancer
27 Aug 2018 //
FIERCE PHARMA
FDA Approves IMBRUVICA + Rituximab as First Non-Chemotherapy Combination
27 Aug 2018 //
PR NEWSWIRE
FDA Approves Imbruvica Plus Rituximab for Rare Blood Cancer
27 Aug 2018 //
R&DMAG
J&J Unit to Sell Sylvant Rights to U.K. Drugmaker Eusa Pharma
18 Jul 2018 //
BLOOMBERG
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ
23 Jan 2018 //
PMLIVE
On World Thalassemia Day, experts call for national policy on prevention genetic
08 May 2017 //
THEWEEK
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.